Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
Kidney International Supplements|January 25, 2019
Genetic and environmental risk factors for chronic kidney diseaseGregorio T Obrador, Ulla T Schultheiss, Matthias Kretzler, et al.
BMC Cancer|July 17, 2016
Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studiesGermaine Wong, Natalie Staplin, Jonathan Emberson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 20, 2024
Canagliflozin and iron metabolism in the CREDENCE trialAkihiko Koshino, Hiddo J L Heerspink, Niels Jongs, et al.
Plos One|February 8, 2013
Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trialJun Hata, Hisatomi Arima, Sophia Zoungas, et al.
Kidney International Supplements|January 25, 2019
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney diseaseCarol Pollock, Anna Zuk, Hans-Joachim Anders, et al.
BMC Public Health|July 1, 2011
Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocolGermaine Wong, Kirsten Howard, Jeremy R Chapman, et al.
Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.
Trials|August 29, 2021
Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trialCarinna Hockham, Sradha Kotwal, Arlen Wilcox, et al.
Scientific Reports|May 27, 2016
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db miceLinda A Gallo, Micheal S Ward, Amelia K Fotheringham, et al.
Journal of the American Society of Nephrology : JASN|October 1, 2020
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A <i>Post</i><i>Hoc</i> Analysis from the CREDENCE TrialMegumi Oshima, Brendon L Neuen, JingWei Li, et al.
Pageof 16